IDEXX Laboratories Posts Higher Revenue, Operating Income, Net Income, and Diluted Earnings Per Share Year-Over-Year in Interim Filing

Bottom line

IDEXX Laboratories, Inc. delivered a stronger year-over-year performance in both the three-month reporting period and the six-month year-to-date period. Revenue, operating income, net income attributable to the parent, and diluted earnings per share were all higher than their respective prior-year comparatives, while remaining profitable on the income statement. This conclusion is supported by the filing’s reported financial data and the authorized year-over-year comparisons.

For IDEXX LABORATORIES INC /DE (IDXX), the filing is identified as 10-Q for period-ended-2026-06-30, under accession 0000874716-26-000123 and CIK 0000874716. The source scope covers the company’s unaudited condensed consolidated financial statements and related accounting-policy disclosures. The reporting periods presented are the three months ended June 30, 2026 and the six months ended June 30, 2026, each compared with the three months ended June 30, 2025 and the six months ended June 30, 2025, respectively.

REPORTING-PERIOD IDENTITY: The filing presents both quarterly and year-to-date results. In the three-month reporting period, revenue was $1,216,585,000, compared with $1,109,457,000 in the prior-year comparative. Operating income was $425,566,000, compared with $373,046,000. Net income attributable to the parent was $338,412,000, compared with $293,989,000, and diluted earnings per share were $4.27 per diluted share, compared with $3.63 per diluted share.

The six-month year-to-date period shows the same directional pattern. Revenue was $2,357,405,000, compared with $2,107,884,000 in the prior-year comparative. Operating income was $788,152,000, compared with $689,580,000. Net income attributable to the parent was $616,858,000, compared with $536,666,000, and diluted earnings per share were $7.74 per diluted share, compared with $6.59 per diluted share.

Management states that the accompanying unaudited condensed consolidated financial statements include the accounts of IDEXX Laboratories, Inc. and reflect, in management’s opinion, all adjustments necessary for a fair statement of financial position and results of operations. Management also says the significant accounting policies used in preparing the statements are consistent with those described in Note 2, subject to the updates discussed in the filing.

The filing explains that changes in deferred revenue during the six-month period were recast and aggregated with other assets and liabilities to reconcile net income to net cash provided by operating activities. Management states that the recast had no impact on net cash provided by operating activities for any period presented.

The filing also describes the company’s revenue presentation. Revenue is disaggregated for the Companion Animal Group based on major product and service categories, while the Water and Livestock, Poultry and Dairy segments comprise a single major product category. Management applies judgment to determine whether products and services are distinct performance obligations that should be accounted for separately.

The reported results indicate broad-based improvement across the company’s income statement during both reporting windows, rather than improvement confined to a single earnings measure. The simultaneous increase in revenue, operating income, net income attributable to the parent, and diluted earnings per share is consistent with stronger reported performance. The filing does not provide enough evidence here to attribute the changes to a particular product, service, geographic area, cost item, or other operating driver.

The statements are unaudited and management cautions that results for the three-month and six-month periods are not necessarily indicative of results expected for the full year or any future period. The filing also notes that preparation of the condensed consolidated financial statements requires estimates, judgments, and assumptions that may affect reported amounts and related disclosures. The presentation of revenue requires management judgment concerning whether products and services are distinct performance obligations.

UNKNOWN: The filing evidence does not provide a peer or industry comparison in this section. The filing evidence contains no peer or industry comparison.

The filing’s unaudited status, recast deferred-revenue presentation, and management’s cautionary language limit how confidently the interim results can be extrapolated beyond the reported periods. The filing evidence does not attribute these changes to any single cause. The filing evidence does not attribute this change to any single cause.

Financial performance

- For the three-month period covered by 10-Q period-ended-2026-06-30, Revenue from Contract with Customer, Excluding Assessed Tax was $1,216,585,000, higher than the prior-year three-month period when it was $1,109,457,000. Reported facts. - For the six-month year-to-date window, Revenue from Contract with Customer, Excluding Assessed Tax was $2,357,405,000, higher than the prior-year six-month comparative of $2,107,884,000. Reported facts. - Operating Income (Loss) for the three-month period was $425,566,000, higher than the prior-year three-month period when it was $373,046,000; the prior year was also a profit, and the current period is a profit. Reported facts. - Operating Income (Loss) for the six-month year-to-date window was $788,152,000, higher than the prior-year comparative of $689,580,000; the prior year was a profit, and the current period is a profit. Reported facts. - Net Income (Loss) Attributable to Parent for the three-month period was $338,412,000, higher than the prior-year three-month period when it was $293,989,000; both periods were profitable. Reported facts. - Net Income (Loss) Attributable to Parent for the six-month year-to-date window was $616,858,000, higher than the prior-year comparative of $536,666,000; both periods were profitable. Reported facts. - Earnings Per Share, Diluted for the three-month period was $4.27 per diluted share USD/SHARES, higher than the prior-year three-month comparative of $3.63 per diluted share USD/SHARES. Reported facts. - Earnings Per Share, Diluted for the six-month year-to-date window was $7.74 per diluted share USD/SHARES, higher than the prior-year comparative of $6.59 per diluted share USD/SHARES. Reported facts. - The filing evidence does not attribute this change to any single cause. - The accounting policies applied in these unaudited condensed consolidated financial statements, as described under Note 2, are consistent with those in the most recent Annual Report except for the noted updates, including the adoption of a Financial Instruments – Credit Losses standard effective January of the current year with no material impact disclosed, and the company’s continuing evaluation of several newer FASB updates covering environmental credit obligations, internal-use software, and expense disaggregation disclosures, none of which has been adopted yet and none of which is described as having a material impact today. Reported facts. - Revenue recognition continues to rely on judgment over distinct performance obligations, transaction price (including constrained variable consideration), and relative standalone selling prices, with multi-year customer commitment arrangements highlighted as the most significant contracts containing multiple performance obligations; the segment called Companion Animal Group (“CAG”) is disaggregated by major product and service categories, while Water and Livestock, Poultry and Dairy (“LPD”) are presented as single product categories. Management explanations. - The filing evidence contains no peer or industry comparison. - Comparisons within this section are limited to the company’s own prior-year periods; quarter-over-quarter movement versus the immediately preceding quarter of the same fiscal year is not addressed by the filing evidence and is therefore not stated here. Analyst inference.

For context on how a similarly structured interim filing can frame year-over-year gains, readers may find parallels in Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows and Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows, though neither substitutes for IDEXX LABORATORIES INC /DE’s reported numbers in this 10-Q for period-ended-2026-06-30 filed under accession 0000874716-26-000123.

Operating drivers and segments

IDEXX LABORATORIES INC /DE reports operating results across multiple reportable segments, with the disclosed disaggregated revenue structure built around a single Companion Animal Group ("CAG") segment that is broken out by major product and service categories, while Water and Livestock, Poultry and Dairy ("LPD") together comprise a single major product category for the purposes of the cited revenue disclosure.

Top-line performance is captured for both the three-month reporting period and the six-month year-to-date period. Revenue from Contract with Customer, Excluding Assessed Tax is $1,216,585,000 USD for the three months ended June 30, 2026, compared with $1,109,457,000 USD for the three months ended June 30, 2025, and is $2,357,405,000 USD for the six months ended June 30, 2026, compared with $2,107,884,000 USD for the six months ended June 30, 2025. Operating Income (Loss) is $425,566,000 USD for the three months ended June 30, 2026 versus $373,046,000 USD for the three months ended June 30, 2025, and $788,152,000 USD for the six months ended June 30, 2026 versus $689,580,000 USD for the six months ended June 30, 2025. The filing itself does not isolate which sub-category within CAG drove the moves, nor does it quantify CAG, Water, or LPD separately beyond the grouping described; the segment-level margin picture is therefore a single-margin total rather than a set of distinct segment operating margins.

Management attributes the period's results to a presentation that disaggregates CAG revenue by major product and service categories, while Water and LPD are treated as a single major product category, with judgment applied to identify distinct performance obligations. Management's stated accounting basis is consistent with the policies described in Note 2 Summary of Significant Accounting Policies in the prior Annual Report, with current-period updates covering the adoption of a credit-loss standard for accounts receivable and contract assets effective January of the current year, which had no material impact, and ongoing evaluation of three not-yet-adopted ASUs covering environmental credit obligations, internal-use software capitalization, and expense disaggregation disclosures. Management also notes that changes in deferred revenue during the six months were recast and aggregated with other assets and liabilities to reconcile net income to net cash provided by operating activities, with no impact on net cash provided by operating activities for any period presented.

The filing evidence does not attribute the period-over-period change in revenue or operating income to any single cause. The filing evidence does not attribute this change to any single cause.

The filing evidence contains no peer or industry comparison. The filing evidence contains no peer or industry comparison.

Readers comparing IDEXX LABORATORIES INC /DE's reported growth to peers filing in the same window — for example, the Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing case — should do so against their own independent peer set rather than relying on anything asserted here. For an example of an interim filing where revenue moved up but every earnings line landed at a loss, see Silicon Laboratories Interim Filing: Revenue Up, Loss on Every Earnings Line, which is a useful contrast pattern even though it is not a direct peer.

Cash flow and capital

The interim cash-flow statement filed for IDEXX LABORATORIES INC /DE under 10-Q for period-ended-2026-06-30 (accession 0000874716-26-000123, CIK 0000874716, ticker IDXX) separates operating, investing, and financing activity cleanly, with the investing and financing lines each reported as net outflows in both windows. Net Cash Provided by (Used in) Operating Activities was $613,410,000 USD for the six-month year-to-date period the six months ended June 30, 2026, compared with $423,705,000 USD for the prior-year comparative the six months ended June 30, 2025, and the authorized year-over-year reading is that operating cash generation increased between the two windows. Net Cash Provided by (Used in) Investing Activities was -$59,040,000 USD for the six months ended June 30, 2026, against -$63,238,000 USD for the six months ended June 30, 2025, and the authorized year-over-year reading is that the investing outflow widened in absolute terms (a larger cash use) compared with the prior year. Within that investing activity, Payments to Acquire Property, Plant, and Equipment were $56,630,000 USD for the six months ended June 30, 2026 versus $64,128,000 USD for the six months ended June 30, 2025, and the authorized year-over-year reading is that capital spending decreased relative to the prior-year window even as the broader investing outflow expanded.

On the financing side, Net Cash Provided by (Used in) Financing Activities was -$536,619,000 USD for the six months ended June 30, 2026, versus -$495,952,000 USD for the six months ended June 30, 2025, and the authorized year-over-year reading is that the financing outflow deepened (more cash used) versus the prior-year comparative. Inside financing, Payments for Repurchase of Common Stock were $697,840,000 USD for the six months ended June 30, 2026 compared with $738,995,000 USD for the six months ended June 30, 2025, and the authorized year-over-year reading is that buyback spending decreased against the prior year. The combination — smaller capex, smaller buyback outflow, yet a larger investing outflow and a larger financing outflow — points to other uses absorbing cash; The filing evidence does not attribute this change to any single cause.. Readers weighing reinvestment intensity against shareholder returns can compare the same authorization pattern in other interim windows, such as the Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows, which uses the same authorization vocabulary for its financing-activity line.

On the balance sheet at the balance sheet date of June 30, 2026, the statement presents the usual liquidity anchors: Cash and Cash Equivalents, at Carrying Value of $196,933,000 USD; Accounts Payable, Current of $129,097,000 USD; and Long-term Debt, Excluding Current Maturities of $299,865,000 USD. The financing-cash commentary in the management discussion ties to the equity movements disclosed under Note 16, while the broader revenue-recognition framework around contract assets, deferred revenue, and customer commitment arrangements is summarized under Note 2; the procedures-and-controls language carried under Item 4 and the quantitative-disclosures language under Item 3 sit alongside, but the cash-flow narrative itself does not need those items to stand up. The filing evidence contains no peer or industry comparison..

Peer and historical context

the filing for IDEXX LABORATORIES INC /DE (IDXX, 10-Q for period-ended-2026-06-30, accession 0000874716-26-000123, CIK 0000874716) frames this section strictly through the company's own year-over-year windows rather than through named peers, because the cited evidence contains no external benchmark set. The reporting periods under review are the three months ended June 30, 2026 versus the three months ended June 30, 2025 for the three-month comparison and the six months ended June 30, 2026 versus the six months ended June 30, 2025 for the six-month comparison, with revenue, operating income, net income, and operating cash flow all readable in both windows. A natural way to widen the context is to compare this trajectory with the similarly structured Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing review, where the same authorized directional language — revenue, operating income, and net income moving higher with profit retained on both windows — applies, even though the underlying business mix is unrelated.

- Revenue from Contract with Customer, Excluding Assessed Tax was $1,216,585,000 USD for the three months ended June 30, 2026 versus $1,109,457,000 USD for the three months ended June 30, 2025, and $2,357,405,000 USD for the six months ended June 30, 2026 versus $2,107,884,000 USD for the six months ended June 30, 2025, with the authorized direction registering as higher than the prior period on both windows. - Operating Income (Loss) was $425,566,000 USD for the three months ended June 30, 2026 versus $373,046,000 USD for the three months ended June 30, 2025, and $788,152,000 USD for the six months ended June 30, 2026 versus $689,580,000 USD for the six months ended June 30, 2025, with profit retained on both sides of each comparison and the authorized direction higher than the prior period. - Net Income (Loss) Attributable to Parent was $338,412,000 USD for the three months ended June 30, 2026 versus $293,989,000 USD for the three months ended June 30, 2025, and $616,858,000 USD for the six months ended June 30, 2026 versus $536,666,000 USD for the six months ended June 30, 2025, again profit on both sides and higher than the prior period in each window. - Net Cash Provided by (Used in) Operating Activities was $613,410,000 USD for the six months ended June 30, 2026 versus $423,705,000 USD for the six months ended June 30, 2025, with the authorized direction reading higher than the prior period on a positive base in both halves. - The revenue-recognition policy described in the cited note discusses contract assets, IDEXX Points, deferred rebate consideration, and lease revenue from reagent rental arrangements, but does not provide any named-peer or industry benchmark for cross-company comparison; The filing evidence contains no peer or industry comparison. applies. - The filing evidence does not attribute this change to any single cause. for the directional gap between the current and prior periods on each of the four measured lines, because the filing evidence does not attribute the movement to any single cause.

Scenario analysis

For the three-month period, the company kept posting profit on both the top line and the bottom line, with revenue from contracts with customers, excluding assessed tax, sitting at $1,216,585,000 USD against the prior-year reading of $1,109,457,000 USD, and net income attributable to parent landing at $338,412,000 USD versus $293,989,000 USD. Across the six-month window, the same profit-to-profit shape held: revenue reached $2,357,405,000 USD against $2,107,884,000 USD, and net income attributable to parent was $616,858,000 USD compared with $536,666,000 USD. That is the base case to anchor any conditional scenarios to, with no margin or mix commentary offered because The filing evidence does not disclose segment-level detail for this dimension. and The filing evidence does not attribute this change to any single cause.. The base path simply assumes the company keeps compounding revenue and earnings on both windows at the pace already in the print, while deferred revenue from multi-year rebate commitments and reagent rental instrument placements continue to convert into recognized revenue as customers take delivery of eligible products.

An upside path would lean on the same revenue and earnings figures the filing already shows. If the three-month run rate of $1,216,585,000 USD and the six-month run rate of $2,357,405,000 USD prove to be a floor rather than a midpoint, the next several periods could compound on top of the prior-year comparatives of $1,109,457,000 USD and $2,107,884,000 USD. Upside on earnings would track the same shape, with the three-month net income reading of $338,412,000 USD and the six-month net income reading of $616,858,000 USD extending the profit-to-profit transition that is already authorized against the prior-year benchmarks of $293,989,000 USD and $536,666,000 USD. The contract economics in the source narrative support that lean: rebate and up-front consideration arrangements carry forward customer commitments for future purchases, and reagent rental placements add lease receivable balances that get reclassified into accounts receivable as customers are billed, so a backlog of committed but unsatisfied performance obligations is in place at the balance sheet date. Readers cross-checking the profit-to-profit pattern can compare it against peer filings such as Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing and Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows.

The downside mirror starts from the same print but assumes those authorized profit-to-profit transitions on revenue and net income narrow rather than extend. If $1,216,585,000 USD against $1,109,457,000 USD flattens, and $2,357,405,000 USD against $2,107,884,000 USD loses momentum, the earnings line follows: $338,412,000 USD relative to $293,989,000 USD, and $616,858,000 USD relative to $536,666,000 USD. The source narrative does not separate instrument, consumable, and service lines, so any mix shift that compresses reagent rental placements or rebate-eligible volume cannot be sized from this filing; The filing evidence does not disclose segment-level detail for this dimension.. The filing evidence does not attribute this change to any single cause.. The filing evidence contains no peer or industry comparison.. Downside risk therefore reads as a deceleration of the authorized profit-to-profit direction rather than a break in profitability.

Risks and what to watch

- Reported and management-stated facts: In this 10-Q for period-ended-2026-06-30 filed by IDEXX LABORATORIES INC /DE (CIK 0000874716, accession 0000874716-26-000123), the top-line moved higher year over year on both reporting windows. Revenue from Contract with Customer, Excluding Assessed Tax was $1,216,585,000 USD for the three months ended June 30, 2026 versus $1,109,457,000 USD for the three months ended June 30, 2025, and $2,357,405,000 USD for the six months ended June 30, 2026 versus $2,107,884,000 USD for the six months ended June 30, 2025.

Net Income (Loss) Attributable to Parent likewise posted a profit-to-profit transition on both windows: $338,412,000 USD versus $293,989,000 USD for the three-month view, and $616,858,000 USD versus $536,666,000 USD for the six-month view, with diluted EPS rising on each comparison per the authorized year-over-year directions. - Management's own commentary focuses on lease-accounting mechanics for reagent rental arrangements rather than operating drivers. The cited note explains that sales-type leases are recognized up front and billed over time, while operating leases are recognized ratably, and discusses the carrying value of lease receivable assets, amounts reclassified to accounts receivable, and credit-loss monitoring.

Impairments and profit-and-loss items recognized at commencement are described as not material, providing no incremental operating risk signal beyond what is already in the numbers. - Analyst inference is constrained to the authorized directions above. Both revenue and net income grew on a year-over-year basis, and the authorized transitions remain profit to profit.

The contrast with filings such as Silicon Laboratories Interim Filing: Revenue Up, Loss on Every Earnings Line is incidental but worth flagging: revenue expansion here coincided with bottom-line expansion, not deterioration. - Counter-evidence and unknowns: The filing evidence does not attribute this change to any single cause. The filing evidence does not attribute the year-over-year revenue or net income movement to any single cause.

The filing evidence contains no peer or industry comparison. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension.

The filing evidence does not disclose segment-level detail for this dimension. Risk-factor updates are addressed under Item 1A and other Part II items under Item 4, but no new quantitative risk disclosure is incorporated into the income statement itself. - Metrics to watch next period: the same two top-of-statement lines — Revenue from Contract with Customer, Excluding Assessed Tax and Net Income (Loss) Attributable to Parent — on both the three-month and six-month windows, since the year-over-year authorized direction is increase on each.

Readers comparing growth profiles across companies can place this result alongside peer coverage such as Broadcom Posts Higher Revenue, Operating Income, and Diluted EPS Year-Over-Year in Filing to gauge whether the profit-to-profit expansion here is broad-based or idiosyncratic.